Member Info for Bunsie

Hi Rats,

Still at EGBJ, all good, still 6 Bj's operating as they should.

I am now a retired Captain, so just running the Company.

ATB

Lindy Durrant

""Strong predictable Durable response""

Takes on a new meaning

we started the trial in January ....17

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces today that following further discussions with the Medicines and Healthcare products Regulatory Agency (MHRA), it has now received approval to add a third cohort to the SCOPE trial. This cohort will recruit 43 advanced unresectable melanoma patients who will receive iSCIB1+ with doublet therapy, consisting of ipilimumab (Yervoy®) plus nivolumab (Opdivo®).

Feb, March, April, May to get to 10 they may have all been scanned we only needed 9 otherwise we could not have got to 22

Work it out

What we do know of ISCIB1 it contains the same epitopes as Scib1

because scib1 treats 40% of the population ...

40% of 15 is 6 thus the trial would fail at simon stage 1 if the iscib1 didn't work in the 60%

if those HLA patients had been separated out and only had scib1 not iscib1

leaving the 60% balance with ISCIB1

then that non futility is very interesting statistic indeed because it's based on non HLA compliance

with the HLA compliant filtered out

which gives comprehensive proof that ISCIB1 works

Chill found an interesting piece on the ASCO presentation which indicates that ISCIB1 is using Simon stage 1/2, it's on the Scancell website.

I have had some more thoughts about Simon stage 1 and 2 use for ISCIB1 cohort 3

9 OF 15 patients is non futility (a point of failure)

The term 'futility' is used to refer to the inability of a clinical trial to achieve its objectives. In particular, stopping a clinical trial

Scancell continues to recruit to the SCOPE study, which includes patients treated with SCIB1 as well as iSCIB1+. 32/43 patients have been recruited into the SCIB1 cohort and 22/43 into the iSCIB1+ cohort, with clinical results expected in Q4 2024 and Q1 2025, respectively.

They have not stopped the trial

Which indicates 9 have achieved a pass otherwise MHRA would have stopped the trial for futility

Worth a look guys over there IMO, in particular Chilltime & Inanaco

Off to my SW facing garden to mow the lawn now! haha

something else i have just noted in trinity ... Never mentioned before on BB's to my knowledge ...

it nearly puts us into a TAX Haven ..... and because of it, i suspect the Board to elevate License agreements above a Sale

Its called Patent Box

hTTps://mmp-tax.co.uk/patent-box.html?gclid=CjwKCAjwp_GJBhBmEiwALWBQk9bXE46tS9kiSuJOCNSKuWrDcjlKjVhfUtDjW691CUPfigdlfB8GTBoCs9gQAvD_BwE

The incentive is designed to encourage companies to commercialise their high-value patent development, R&D and retain manufacturing jobs in the UK.

Businesses that are liable to pay UK Corporation Tax need to show they've made profit from qualifying patented inventions. Patents must have been granted by the UK Intellectual Property Office or the European Patent Office, as well as administrations in some other qualifying European territories. But once the IP is patented, worldwide income from it (such as licensing and royalties) becomes eligible.

If you can't claim under Patent Box now, or don't know if you can, then you should be taking steps today to make sure you can claim in the future. You can seek advice from us on a no obligation basis.

Evening Wild,

I have dabbled on a few shares, one came good but the rest bombed out, so no not my game really.

Scancell is something quite different to me me so sitting quietly and waiting, win or lose, I really enjoy following this Bio.
ATB
Bunsie

Hi Wild,
I am fine thanks, enjoy your positive postings very much.

I am not a trader, just invested after following the science, which many have kindly posted here over the years.

To all who have contributed, thank you.

ATB
Bunsie

Hasiba

You may think you know what you are doing, but your performance over the last few days has been chaotic.

Inanaco has vast experience on the technical side of Scancell and I know that he has an excellent rapour with Lindy .. and indeed the Journalist that kick started this rise, and can back up everything posted, with research using third party data which then backs up the science of Scancell.

Like myself he also has substantial holdings.

But no worries as you can never tell a gambler that he has an addiction , some you win some you lose like your 6m MTFB shares
ouch !

From memory Inanaco told us not to touch that one ... or Val for that matter

ATB
Bunsie

Dear Hash,

That is your choice, put me on fikter as you say.

Struck a nerve then with you.

I only post from Inan which I think to be beneficial to this BB, everyone can take what they wish from it, nothing more.

I am fairly neutral and enjoy everybodies opinions, just a shame that Inan has been barred from LSE due to VAL postings

As I am on your filter you may not see this post, put your toys back into the pram and grow a pair!

ATB to you anyway
Bunsie

Hasiba, reply from Inan from your 09.14 today, I thought it was important to us all on this BB

your text highlighted "" ""

"" The more the virus mutates the weaker it gets and this may be the case here ""

wrong its got more infective and more deadly by quite a margin the kent variant , the P1 variant has shown it ""can reinfect""that is a major shift

up from 10/1000 deaths to 13/1000 deaths for the kent variant, the P1 strain carries the same mutations and more.


""current vaccines can easily be tweaked for the slow mutation of Covid19""

yes they can, but getting them into arms is the hard part

you still have to vaccinate against all strains so even if you wanted another vaccine given as a booster to broaden the response you still have to complete the first vaccination process .... while you are doing that, the virus will have pressure to circumvent the first vaccinations as they do not as yet sterilise ie block infection.

"""We need to be mindful that there are over 300 companies trying to produce Covid19 vaccines too and I for one like to think sclp is a mix of great innovative valuable products in addition to Covid19 vaccine ...rather than focusing on covidity only from here...""

we are mindful ... but only a handful are capable of building complex vaccine and only a very select few have attempted a cancer vaccine, those that have failed cancer might get saved by check points like keytruda or are so prohibitively expensive can never be used for general vaccination ... Car T .. a Proven Cancer Vaccine is far more potent then any viral vaccine

"""All in all We are getting out from this pandemic."""

the UK may well be ... but what about the rest of the planet ?

the economic consequence of that affects the UK ....

ok here we go this is the Big One ...........

this is what devastated Manaus Brazil ......

This is ""NOT"" a Variant ........ its a "lineage" or "strain"

Six cases of the Brazilian coronavirus variant have been identified in the UK, Public Health England has said.

It is the first time the variant, known as P.1, has been identified in the UK.

Two of the cases are from one household in South Gloucestershire, with a history of travel to Brazil.

Two additional people in the Gloucestershire household have tested positive, but gene sequencing has not yet confirmed if they have the P.1 variant.

The third case is currently unlinked and an investigation is underway to find the individual as they did not fill in their test registration card so follow-up details are not available, PHE said.

Three more cases have been identified in Scotland.

The P.1 variant, first detected circulating in Manaus, northern Brazil, by scientists in December, is thought to be similar to the South African variant in evading vaccines.

But PHE said more work is needed to understand this possibility.

PHE is now tracing all passengers on a return flight from Sao Paulo, Brazil - Swiss Air flight LX318 via Zurich landing in London Heathrow on February 10.

Those returning to the UK should have immediately quarantined at home for 10 days.

Surge testing will also be deployed in South Gloucestershire as well as increasing sequencing of positive samples from the area.

Dr Susan Hopkins, PHE strategic response director for Covid-19 and NHS Test and Trace Medical Advisor, said: “We have identified these cases thanks to the UK’s advanced sequencing capabilities which means we are finding more variants and mutations than many other countries and are therefore able to take action quickly.”

Telegraph

Great link from Inan, so felt I should share it........

""""We next compared TCR avidities and clonalities of SARS-CoV-2-reactive T cells from hospitalized versus non-hospitalized patients. SARS-CoV-2-reactive T cells from hospitalized patients displayed """lower functional avidity""" than did those from non-hospitalized patients (Figures 6E–6G) and similar to those from unexposed donors (Figure 3D).
In line with this, SARS-CoV-2-specific T cells from hospitalized COVID19 patients showed a trend toward a more diverse TCR repertoire""""

hTTps://www.cell.com/immunity/pdf/S1074-7613(20)30503-3.pdf

Scancell Vaccine delivers "High Avidity" ................. its what we do

and HERE is the proof that we Need it ...........

From Inan
Its the Data that comes out of Scancell ..... that is important

debating if its weeks or months is pointless ...

Until all the hurdles are passed ie. toxicology, stability etc Time Scales can only be a predication .. its impossible to punish Scancell if that slips .. we are not an assembly line, cutting edge science coupled with "new Process" for instance adding Amplivant to Moditope and switching to Hydrophobic proteins creates technical issues that have to be overcome .....But the Trial is the Expensive bit ... its the Trial that generates the biggest value and its the Trial in Humans that has to be safe. If Scancell goes alone into trial its because it understands the Risk, after all Scancell is developing its own invention ... if Big Pharma was so good at it why don't they "invent"

How Tuff Ruck and Hasiba have that "knowledge" is beyond me . nothing in there posting history points to them being experts in the science or even a basic understanding to be able to articulate the science and even having any nous in the commercial sphere to Act as an equal to CH .... and if they had why are they not running a PLC instead of posting as anonymous keyboard warriors

yet again "Common Sense" rarely gets posted

Bermuda Has this one spot on .... so has my backing

Big Pharma wants to buy the Science not the Personalities .......

everything revolves around the science

its as simple as that ..........

If it gets funded ... somebody thinks its commercial and CH has done his Job ...

challenging to develop than those designed to prime the immune system against infectious agents. Tumours are much more heterogenous and it may be that a personalised approach is required, in which case the selection of the most appropriate neoantigen is vital and there are additional time constraints that must be considered. Additionally, clinical trial endpoints are necessarily much longer, especially for therapies utilised in the adjuvant setting. Finally, now that the efficacy of mRNA vaccines against the novel coronavirus has been demonstrated, companies may choose to go after much lower-hanging fruit; the seasonal influenza vaccine, for example, would be a highly lucrative space. That being said, this is likely to be a much more active area of research, with a considerably increased investment that could drive important advances in cancer vaccines.

........
challenging to develop than those designed to prime the immune system against infectious agents. Tumours are much more heterogenous and it may be that a personalised approach is required, in which case the selection of the most appropriate neoantigen is vital and there are additional time constraints that must be considered. Additionally, clinical trial endpoints are necessarily much longer, especially for therapies utilised in the adjuvant setting. Finally, now that the efficacy of mRNA vaccines against the novel coronavirus has been demonstrated, companies may choose to go after much lower-hanging fruit; the seasonal influenza vaccine, for example, would be a highly lucrative space. That being said, this is likely to be a much more active area of research, with a considerably increased investment that could drive important advances in cancer vaccines.

This article Highlights why Scancell is massive and why £8 is not unrealistic

It highlights what i have been saying for the last few years

it also highlights how difficult cancer vaccines are to Virus

in fact i could have written it ........... and probably have if you combine posts

hTTps://www.clinicaltrialsarena.com/comment/moderna-biontech-covid-cancer-vaccines/

The remarkable speed at which both Moderna and Pfizer / BioNTech were able to develop their highly efficacious Covid-19 vaccines has brought mRNA-based technology into the mainstream. Both Moderna and BioNTech have been developing mRNA-based vaccines for a range of conditions for many years, but currently, none of these have been approved. However, could their success in developing Covid-19 vaccines lead to a renewed enthusiasm for mRNA-based cancer vaccines?

Cancer vaccines have been in development for many years, but high-profile failures and limited results have meant there has not been a great deal of interest in this approach in recent years. However, following the success of the Covid-19 vaccines, investors may be much keener to back these technologies, both due to the demonstrated safety in a large cohort of patients, as well as the impressive efficacy of this approach. Furthermore, the considerable revenue both Moderna and BioNTech can expect from their Covid-19 vaccines means that these companies will have the funds needed for clinical trials.

While the mRNA-based vaccines against Covid-19 (and those in development for other infectious diseases) focus on prevention, cancer vaccines are designed to treat tumours by stimulating an immune response and are unlikely to be used as a stand-alone therapy. Moderna currently has two cancer vaccines in clinical trials (partnered with Merck); the most advanced of these, mRNA-4157, is a personalised vaccine that delivers neoantigens selected from the patient’s tumour and is being tested in a Phase II trial for the adjuvant treatment of melanoma and in a Phase I trial for the treatment of solid tumours, in both cases in combination with Merck’s Keytruda. Interim results from the Phase I trial appear promising, with an overall response rate of 50% in a small sample of patients with head and neck squamous cell carcinoma. Meanwhile, BioNTech has several cancer vaccines in development and early-stage clinical trials. One, BNT111, is currently being tested in a Phase I trial in melanoma patients and is composed of four melanoma antigens. However, interim results were underwhelming. A second candidate from BioNTech in collaboration with Roche / Genentech is a personalised vaccine being tested in advanced melanoma patients in a Phase II trial in combination with Keytruda, with results expected later this year.

Despite the successes of these mRNA-based vaccines against Covid-19, cancer vaccines using similar technologies are still unlikely to be available for several years. Cancer vaccines are considerably more challen

Crumbs,
Sorry about that, been out of the BB today.

Perhaps I have a bit of "brain fog" after my Pfizer jab yesterday, although all I have at the moment is a slightly sore arm.

ATB
Bunsie

https://www.telegraph.co.uk/news/2021/02/13/exclusive-universal-vaccine-can-conquer-covid-variants-could/

Exclusive: 'Universal vaccine' that can conquer all Covid variants could be developed in less than a year, researchers say
A universal vaccine that would work on all Covid-19 variants by targeting the core of the virus instead of the spike protein could be available in as little as a year, researchers say.
www.telegraph.co.uk

Kash, yes lazy I am.

Perhaps still in shock.

I think we have a good team here to advise, so will sign off for now.

Catch up in the morning
Thank you LL
and Thank you all.

ATB

Evening all,

Had the Pfizer vaccine (first one) at 14.30 today, which was unexpected, thought it would be the AZ.

My research has been on the AZ so am behind the curve on the Pfizer vaccine now.

Any info on the Pfizer one would be appreciated based on one dose.

Many thanks in advance for any info on efficacy, morbitity, protection would be appreciated.

Thanks team Scancell.
ATB